Walgreens ends buy limits on children's fever medicines

By AP News

Share:

Walgreens has ended a limit it imposed recently for online purchases of children’s over-the-counter fever reducing products

Walgreens-Results

Walgreens has ended limits it had imposed recently for online purchases of children’s over-the-counter fever reducing products.

The drugstore chain said improved supplies allowed it to lift its restriction of six products. The company had placed no limit on in-store purchases.

Last month both Walgreens and CVS Health restricted purchases of some over-the-counter children’s medicines citing supply issues. CVS Health put a two-product limit on all children’s pain relief products bought through its pharmacies or online.

A CVS Health spokeswoman said Tuesday that limits on some children's medicines remain in place. She did not offer a time frame for when it might end.

An unusually fast start to the annual U.S. flu season, plus a spike in other respiratory illnesses, created a surge in demand for fever relievers and other products people can buy without a prescription.

Shortages of medicines like Children’s Tylenol developed, varying around the country and sometimes even within communities.

Experts who track medicine shortages said in December that the problem could persist through the winter cold-and-flu season. But they noted that it should not last as long as other recent shortages of baby formula or prescription drugs.

Share:

Author: AP News

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Originally published by Associated Press Valuethemarkets.com, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

Sign up for Investing Intel Newsletter